Staggering imbalance with cancer treatments funded by Pharmac
Despite lung cancer being NZ’s Biggest Cancer Killer, the top 3 lung cancer drugs funded by Pharmac (2017/18) equates to just 2.3% of the top 5 cancer drugs ($122 million).
Despite lung cancer being NZ’s Biggest Cancer Killer, the top 3 lung cancer drugs funded by Pharmac (2017/18) equates to just 2.3% of the top 5 cancer drugs ($122 million).